These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 14981996

  • 1. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 2. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K.
    Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
    [Abstract] [Full Text] [Related]

  • 3. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK.
    Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
    [Abstract] [Full Text] [Related]

  • 5. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
    Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D.
    Anticancer Res; 2000 Apr; 20(6D):5095-8. PubMed ID: 11326675
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

  • 7. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999 Jun; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 8. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Jun; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 9. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y, Pinedo IR, Tapuria N, Zabron A, Davidson BR.
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [Abstract] [Full Text] [Related]

  • 10. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW.
    Anticancer Res; 2003 Oct; 23(2A):1127-30. PubMed ID: 12820359
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
    Li YG, Zhang N.
    Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tumor M2-PK levels in haematological malignancies.
    Oremek GM, Rox S, Mitrou P, Sapoutzis N, Sauer-Eppel H.
    Anticancer Res; 2003 Aug; 23(2A):1135-8. PubMed ID: 12820361
    [Abstract] [Full Text] [Related]

  • 18. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
    Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G.
    Anticancer Res; 1997 Aug; 17(4B):3153-6. PubMed ID: 9329624
    [Abstract] [Full Text] [Related]

  • 19. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer.
    Pottek T, Müller M, Blum T, Hartmann M.
    Anticancer Res; 2000 Aug; 20(6D):5029-33. PubMed ID: 11326662
    [Abstract] [Full Text] [Related]

  • 20. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
    Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S, Seiffert UB.
    Anticancer Res; 1997 Aug; 17(4B):3031-3. PubMed ID: 9329593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.